Allogeneic SCT May Be Effective for Some With Advanced Cutaneous T Cell Lymphomas
the ONA take:
Allogeneic stem cell transplantation may result in long-term remissions in a subset of patients with advanced cutaneous T cell lymphomas (CTCL), a new study published online ahead of print in the journal Annals of Oncology has shown.
Because patients with advanced CTCL and large cell transformation are incurable with standard treatments, researchers from The University of Texas MD Anderson Cancer Center in Houston sought to evaluate the outcomes of patients with advanced CTCL undergoing allogeneic stem cell transplantation.
In the prospective case series, researchers report the outcomes of 47 patients with CTCL who underwent allogeneic stem cell transplantation after failure of standard therapy.
Results showed that 4-year overall survival was 51% and 4-year progression-free survival was 26%. Researchers found that 4-year progression-free survival was superior in patients who had leukemic Sézary Syndrome, a common variant of CTCL, compared with those who did not.
In regard to safety, the cumulative incidences of grades 2 to 4 acute graft-versus-host disease (GVHD) and chronic GVHD were 40% and 28%, respectively.
“Although post-SCT relapse rates are high, many patients respond to immunomodulation and achieve durable remissions,” the authors conclude.
Allogeneic stem cell transplantation may result in long-term remissions in a subset of patients with cutaneous T cell lymphomas.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|